ClinicalTrials.gg
CompletedNCT05533411Updated Oct 4, 2024Results posted

A Study of Donanemab (LY3002813) in Healthy Chinese Participants

A Phase 1 interventional study of Donanemab and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-04.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate the safety and tolerability of donanemab (LY3002813) when administered as single dose in healthy Chinese participants. The study will also assess how fast donanemab gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 85 days.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation
  • Participants are native Chinese participants. To qualify as a native Chinese, the participant, the participant's biological parents, and all four of the participant's biological grandparents must be of Chinese origin.
  • Have a (BMI) of 18.0 and 28.0, kilograms per meter squared (kg/m²), inclusive.

Exclusion criteria

Exclusion Criteria:

  • Are lactating.
  • Are women of .
  • Have known allergies to donanemab, related compounds or any components of the formulation or history of significant atopy.
  • Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within three months or five half-lives (whichever is longer) prior to dosing.
  • Have participated, within the last 30 days, in a clinical study involving an product; at least five half-lives or 30 days (whichever is longer) should have passed.
  • Have history of intracranial hemorrhage, cerebrovascular aneurysm or arteriovenous malformation, or carotid artery occlusion, stroke or epilepsy.
  • Participants who show evidence of positive antibodies, or positive antibody, or positive surface antigen
  • Have had leukemia, lymphoma, or any within the past five years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for three years. Have had breast cancer within the past 10 years.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    350 milligram (mg) Donanemab

    Single 350 mg Donanemab dose administered intravenously (IV) on Day 1.

    Drug: Donanemab

  • Experimental
    700 mg Donanemab

    Single 700 mg Donanemab dose administered IV on Day 1.

    Drug: Donanemab

  • Experimental
    1400 mg Donanemab

    Single 1400 mg Donanemab dose administered IV on Day 1.

    Drug: Donanemab

  • Placebo comparator
    Placebo

    Single placebo dose administered IV on Day 1.

    Drug: Placebo

Interventions

  • Administered IV.

    Also known as: LY3002813

  • DrugPlacebo

    Administered IV.

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is located in the Reported Adverse Event module. Drug related TEAEs are any untoward medical occurrences that either occurs postdose or presents prior to dosing yet becomes more severe postdose, and in the opinion of the investigator is possibly related to study drug.

    Time frame: Baseline up to Day 85

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Donanemab

    PK: Cmax of Donanemab

    Time frame: Predose, Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57 and 85 postdose

  2. PK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Donanemab

    PK: AUC\[0-∞\] of Donanemab

    Time frame: Predose, Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57 and 85 postdose

07

Results

Posted Oct 4, 2024

Participant flow

Participant flow — Overall Study
MilestonePlacebo350 Milligram (mg) Donanemab700 mg Donanemab1400 mg Donanemab
Started6101010
Received at least 1 dose of study drug6101010
Completed6101010
Not completed0000

Outcome measures

PrimaryNumber of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is located in the Reported Adverse Event module. Drug related TEAEs are any untoward medical occurrences that either occurs postdose or presents prior to dosing yet becomes more severe postdose, and in the opinion of the investigator is possibly related to study drug.

Time frame:
Baseline up to Day 85
Reported as:
Number · participants
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
participantsPlacebo350 mg Donanemab700 mg Donanemab1400 mg Donanemab
Treatment-emergent Adverse Events1200
Serious Adverse Events0000
SecondaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Donanemab

PK: Cmax of Donanemab

Time frame:
Predose, Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57 and 85 postdose
Reported as:
Geometric mean · microgram per milliliter (μg/mL)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Donanemab
microgram per milliliter (μg/mL)350 mg Donanemab700 mg Donanemab1400 mg Donanemab
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Donanemab119 ± 13236 ± 9539 ± 30
SecondaryPK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Donanemab

PK: AUC\[0-∞\] of Donanemab

Time frame:
Predose, Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57 and 85 postdose
Reported as:
Geometric least squares mean · microgram * hour/milliliter (μg.h/mL)
PK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Donanemab
microgram * hour/milliliter (μg.h/mL)350 mg Donanemab700 mg Donanemab1400 mg Donanemab
PK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Donanemab9050 ± 2322600 ± 1753100 ± 27

Adverse events

Collected over Baseline up to 85 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/6 (0%)0/6 (0%)5/6 (83.3%)
350 Milligrams (mg) Donanemab0/10 (0%)0/10 (0%)6/10 (60%)
700 mg Donanemab0/10 (0%)0/10 (0%)4/10 (40%)
1400 mg Donanemab0/10 (0%)0/10 (0%)5/10 (50%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlacebo350 Milligrams (mg) Donanemab700 mg Donanemab1400 mg Donanemab
Blood uric acid increasedInvestigations3/61/101/100/10
Asymptomatic COVID-19Infections and infestations1/61/101/103/10
COVID-19Infections and infestations0/60/102/101/10
Upper respiratory tract infectionInfections and infestations1/60/100/101/10
Blood creatine phosphokinase increasedInvestigations1/61/101/100/10
Blood urea increasedInvestigations1/60/100/100/10
DizzinessNervous system disorders1/60/100/100/10
Allergy to arthropod biteImmune system disorders0/61/100/100/10
Otitis mediaInfections and infestations0/60/101/100/10
Alanine aminotransferase increasedInvestigations0/61/100/100/10

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Placebo350 mg Donanemab700 mg Donanemab1400 mg DonanemabTotal
Mean27.0 ± 7.028.1 ± 6.232.8 ± 4.527.9 ± 5.829.2 ± 6.0
Sex: Female, Male
Sex: Female, Male(Participants)Placebo350 mg Donanemab700 mg Donanemab1400 mg DonanemabTotal
Female00000
Male610101036
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo350 mg Donanemab700 mg Donanemab1400 mg DonanemabTotal
American Indian or Alaska Native00000
Asian610101036
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Placebo350 mg Donanemab700 mg Donanemab1400 mg DonanemabTotal
China610101036
08

Study locations

2 sites
  • Peking University First Hospital
    Beijing, Beijing 100034, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Jan 2023, 3 months.

Results were first posted in Oct 2024, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2022
First posted
Sep 9, 2022
StartActual
Sep 14, 2022
Primary completionActual
Jan 5, 2023
CompletionActual
Jan 5, 2023
Results first posted
Oct 4, 2024
Last update
Oct 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05533411
Responsible party
Sponsor
First posted
Sep 9, 2022
Start date
Sep 14, 2022
Primary completion
Jan 5, 2023
Completion
Jan 5, 2023
Results posted
Oct 4, 2024
Last update
Oct 4, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donanemab

Start the discussion